Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth
Authors:
- 6 September 2022
- journal article
- research article
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (11) , 2318-2328
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast CancerClinical Cancer Research, 2017
- Klippel–Trenaunay syndrome belongs to the PIK3CA‐related overgrowth spectrum (PROS)Experimental Dermatology, 2015
- The Lymphatic Malformation Function (LMF) InstrumentOtolaryngology–Head and Neck Surgery, 2015
- Successful Treatment of Macroglossia Due to Lymphatic Malformation With SirolimusAnnals of Otology, Rhinology & Laryngology, 2015
- Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CAThe Journal of Pediatrics, 2015
- PIK3CA‐related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluationAmerican Journal of Medical Genetics Part A, 2014
- Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrumAmerican Journal of Medical Genetics Part A, 2014
- PIK3CA Activating Mutations in Facial Infiltrating LipomatosisPlastic and Reconstructive Surgery, 2014
- Lymphocytopenia in Children With Lymphatic MalformationJAMA Otolaryngology–Head & Neck Surgery, 2006
- Lymphatic Malformations of the Head and Neck: A Proposal for StagingJAMA Otolaryngology–Head & Neck Surgery, 1995